olfactory receptor family 5 subfamily BK member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR5BK1P profile across patient tissues and cancer cell-line models. OR5BK1P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR5BK1P is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, OR5BK1P RNA expression shows 17,310 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, CHOL, and THYM as cancer lineages where OR5BK1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5BK1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5BK1P survival associations across molecular data types. OR5BK1P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5BK1P RNA expression–survival associations across cancer types. High OR5BK1P expression shows unfavorable associations in MESO, but favorable associations in BRCA, ESCA, BLCA, ACC and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for OR5BK1P RNA expression.
This table summarizes OR5BK1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR5BK1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5BK1P shows lower tumor expression in UCEC and BRCA and higher tumor expression in CHOL, LUSC and COAD. The CHOL box plot shows higher OR5BK1P RNA expression in tumor versus normal tissue (log2 FC = +0.450, t-test p = .011).
This table shows molecular features associated with OR5BK1P in patient tissues and cancer cell lines. In patient samples, OR5BK1P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
